1. In Vivo
  2. >>Market Access

Pharma’s Digital Pathology Build-Out; Part 2 – What It Means

 
• By Rachel Laing, Sophie Peltre, and Mark Ratner

Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.  

Access
Users of digital pathology are positive clinical use cases can surmount issues around access • Source: Shutterstock

As we discussed in Part 1 of this article, pharma is deriving value from applications of digital pathology across the spectrum of drug discovery and development. However, despite its promise, providers and users will need to advocate to successfully seed digital pathology across the commercial lab space.

One of the hold-ups is the need to consider whether a digital pathology-oriented companion diagnostic has a home in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

Trump II, Year One: Updated Version Seems Buggy For Pharma

 
• By Nielsen Hobbs

Issues that had been concerns in Trump’s first term are realities now, but industry has also seen some successes. Trump’s personalistic style of governance means that larger firms may be at an advantage because of their greater flexibility to cut deals on individual products.

Legal Challenges Mount Over Germany’s Controversial Combination Rebate

 
• By Francesca Bruce

The pharmaceutical industry has been pushing back on a deeply unpopular rebate on products deemed to be “free combination” medicines in Germany.

EU, UK & Switzerland Speed Up Trials To Regain Global Edge

 
• By Vibha Sharma

Amid a decline in global clinical research share, the EU, UK and Switzerland have launched initiatives for fast-track reviews of clinical trial applications and set ambitious targets to shorten trial setup times.

Wealth Of MedTech Innovator Asia Pacific Entries Underlines Rising Caliber Of Local Technologies

 
• By Ashley Yeo

The culmination of the MedTech Innovator APAC awards program 2025 comes later this month when the top prizes are handed out at the grand final in Singapore. But all cohort companies benefit from the competition’s mentoring process, says awards organizer Fredrik Nyberg.

More from In Vivo

ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026

 
• By Lucie Ellis-Taitt

“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.

Deals In Depth: October 2025

 
• By Maureen Riordan and Deanna Kamienski

Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.

Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines

 
• By Shannon Fisher and Heidi Chen

In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.